Compare PCLA & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCLA | PHIO |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7M | 12.3M |
| IPO Year | 2025 | N/A |
| Metric | PCLA | PHIO |
|---|---|---|
| Price | $5.06 | $1.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.67 |
| AVG Volume (30 Days) | 41.6K | ★ 10.5M |
| Earning Date | 02-13-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,065,197.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.26 | N/A |
| 52 Week Low | $3.46 | $0.81 |
| 52 Week High | $294.00 | $4.19 |
| Indicator | PCLA | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 63.77 | 75.97 |
| Support Level | $4.88 | $0.81 |
| Resistance Level | $5.95 | $1.48 |
| Average True Range (ATR) | 0.83 | 0.14 |
| MACD | -0.11 | 0.06 |
| Stochastic Oscillator | 14.29 | 79.42 |
PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.